Literature DB >> 29780703

Stage III non-small cell lung cancer: escalation matters, but how?

Aparna Madhukeshwar Hegde1, Paul Raymond Walker1.   

Abstract

Entities:  

Year:  2018        PMID： 29780703      PMCID： PMC5943225          DOI： 10.21037/tlcr.2018.03.02

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  18 in total

1.  Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.

Authors:  Kristin A Higgins; Rathi N Pillai; Zhengjia Chen; Sibo Tian; Chao Zhang; Pretesh Patel; Suchita Pakkala; Jay Shelton; Seth D Force; Felix G Fernandez; Conor E Steuer; Taofeek K Owonikoko; Suresh S Ramalingam; Jeffrey D Bradley; Walter J Curran
Journal:  J Thorac Oncol       Date:  2017-09-13       Impact factor: 15.609

2.  Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.

Authors:  Zhongxing Liao; J Jack Lee; Ritsuko Komaki; Daniel R Gomez; Michael S O'Reilly; Frank V Fossella; George R Blumenschein; John V Heymach; Ara A Vaporciyan; Stephen G Swisher; Pamela K Allen; Noah Chan Choi; Thomas F DeLaney; Stephen M Hahn; James D Cox; Charles S Lu; Radhe Mohan
Journal:  J Clin Oncol       Date:  2018-01-02       Impact factor: 44.544

3.  Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.

Authors:  Amit A Lugade; James P Moran; Scott A Gerber; Robert C Rose; John G Frelinger; Edith M Lord
Journal:  J Immunol       Date:  2005-06-15       Impact factor: 5.422

4.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.

Authors:  Sandra Demaria; Noriko Kawashima; Anne Marie Yang; Mary Louise Devitt; James S Babb; James P Allison; Silvia C Formenti
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

5.  Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.

Authors:  Joe Y Chang; Vivek Verma; Ming Li; Wencheng Zhang; Ritsuko Komaki; Charles Lu; Pamela K Allen; Zhongxing Liao; James Welsh; Steven H Lin; Daniel Gomez; Melenda Jeter; Michael O'Reilly; Ronald X Zhu; Xiaodong Zhang; Heng Li; Radhe Mohan; John V Heymach; Ara A Vaporciyan; Stephen Hahn; James D Cox
Journal:  JAMA Oncol       Date:  2017-08-10       Impact factor: 31.777

6.  External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.

Authors:  Mala Chakraborty; Scott I Abrams; C Norman Coleman; Kevin Camphausen; Jeffrey Schlom; James W Hodge
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

7.  Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.

Authors:  Mark A Socinski; A William Blackstock; Jeffrey A Bogart; Xiaofei Wang; Michael Munley; Julian Rosenman; Lin Gu; Gregory A Masters; Peter Ungaro; Arthur Sleeper; Mark Green; Antonius A Miller; Everett E Vokes
Journal:  J Clin Oncol       Date:  2008-05-20       Impact factor: 44.544

8.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

9.  Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.

Authors:  Jonathan Feddock; Susanne M Arnold; Brent J Shelton; Partha Sinha; Gary Conrad; Li Chen; John Rinehart; Ronald C McGarry
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-12-19       Impact factor: 7.038

10.  High-dose concurrent chemo-proton therapy for Stage III NSCLC: preliminary results of a Phase II study.

Authors:  Yoshiko Oshiro; Toshiyuki Okumura; Koichi Kurishima; Shinsuke Homma; Masashi Mizumoto; Hitoshi Ishikawa; Masataka Onizuka; Mitsuaki Sakai; Yukinobu Goto; Nobuyuki Hizawa; Yukio Sato; Hideyuki Sakurai
Journal:  J Radiat Res       Date:  2014-05-25       Impact factor: 2.724
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.